Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California. Show more
1841 Page Mill Road, Palo Alto, CA, 94304, United States
Start AI Chat
Market Cap
869.7M
52 Wk Range
$13.88 - $33.20
Previous Close
$27.59
Open
$27.35
Volume
363,618
Day Range
$27.35 - $28.35
Enterprise Value
1.051B
Cash
76.06M
Avg Qtr Burn
-9.635M
Insider Ownership
12.13%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
EVO301 (IL-18 Inhibitor) Details Moderate-To-Severe Atopic Dermatitis | Phase 2a Data readout |